N-[6-cyano-5-methyl-2-(3,4,5-trimethoxyphenyl)thieno[2,3-d]pyrimidin-4-yl]-β-alanine | 731856-62-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-[6-cyano-5-methyl-2-(3,4,5-trimethoxyphenyl)thieno[2,3-d]pyrimidin-4-yl]-β-alanine
• 英文别名: 3-[[6-Cyano-5-methyl-2-(3,4,5-trimethoxyphenyl)thieno[2,3-d]pyrimidin-4-yl]amino]propanoic acid
• CAS: 731856-62-5
• 化学式: C₂₀H₂₀N₄O₅S
• 分子量: 428.469
• InChiKey: NPCXMNJZKAFVIQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  155
• 氢给体数：
  2
• 氢受体数：
  10

文献信息

• [EN] 4-AMINOTHIENO[2,3-d]PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS<br/>[FR] DERIVES DE 4-AMINOTHIENO[2,3-D]PYRIMIDINE-6-CARBONITRILE UTILISES COMME INHIBITEURS DE PDE7
  申请人：ALMIRALL PRODESFARMA SA

  公开号：WO2004065391A1

  公开（公告）日：2004-08-05

  New 4-aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives having the chemical structure of general formula (I), and pharmaceutically acceptable salts thereof are disclosed as well as processes for their preparation and to pharmaceutical compositions containing them and their use in the treatment, prevention or suppression of pathological conditions, diseases and disorders susceptible of being improved by inhibition of PDE7.

  揭示了具有通用式(I)的化学结构的新4-氨基噻吩[2,3-d]嘧啶-6-碳腈衍生物，以及其药学上可接受的盐，以及它们的制备过程、含有它们的药物组合物以及它们在治疗、预防或抑制通过抑制PDE7可改善的病理状况、疾病和疾病的用途。
• [EN] INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE<br/>[FR] COMPOSES D'INDAZOLE ET COMPOSITIONS PHARMACEUTIQUES INHIBANT LES PROTEINES KINASES, ET PROCEDES D'UTILISATION DE CEUX-CI
  申请人：AGOURON PHARMA

  公开号：WO2001002369A2

  公开（公告）日：2001-01-11

  Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  本文描述了调节和/或抑制某些蛋白激酶活性的吲唑化合物。这些化合物和含有它们的药物组合物能够介导酪氨酸激酶信号转导，从而调节和/或抑制不需要的细胞增殖。本发明还涉及含有这些化合物的药物组合物的治疗或预防用途，并通过给予有效量的这些化合物的方法治疗癌症和其他与不需要的血管生成和/或细胞增殖有关的疾病状态，例如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣。
• INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE
  申请人：——

  公开号：US20040220248A1

  公开（公告）日：2004-11-04

  Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  本文介绍了调节和/或抑制某些蛋白激酶活性的吲唑类化合物。这些化合物及含有它们的药物组合物能够介导酪氨酸激酶信号转导，从而调节和/或抑制不必要的细胞增殖。本发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及通过给予有效量的这些化合物来治疗癌症和其他与不必要的血管生成和/或细胞增殖相关的疾病状态，如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣的方法。
• 4-Aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives as pde7 inhibitors
  申请人：Terricabras Belart Emma

  公开号：US20060229306A1

  公开（公告）日：2006-10-12

  New 4-aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives having the chemical structure of general formula (I), and pharmaceutically acceptable salts thereof are disclosed, as well as processes for their preparation and to pharmaceutical compositions containing them and their use in the treatment, prevention or suppression of pathological conditions, diseases and disorders susceptible of being improved by inhibition of PDE7.

  本发明公开了具有一般式(I)的化学结构的新4-氨基噻吩[2,3-d]嘧啶-6-腈衍生物及其药学上可接受的盐，以及制备它们的方法和包含它们的制药组合物，以及它们在治疗、预防或抑制通过抑制PDE7改善的病理状况、疾病和障碍中的使用。
• Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
  申请人：AGOURON PHARMACEUTICALS, INC.

  公开号：EP1614683B1

  公开（公告）日：2007-11-21